PL1737847T3 - Nebiwolol i jego farmaceutycznie dopuszczalne sole, proces ich przygotowania i kompozycje farmaceutyczne nebiwololu - Google Patents

Nebiwolol i jego farmaceutycznie dopuszczalne sole, proces ich przygotowania i kompozycje farmaceutyczne nebiwololu

Info

Publication number: PL1737847T3
Authority: PL; Poland
Prior art keywords: nebivolol; pharmaceutically acceptable; acceptable salts; preparation; pharmaceutical compositions
Prior art date: 2004-07-30

Application number

PL05815690T

Other languages

English (en)

Inventor

Rakesh Sheth

S V Attanti

Hasmukh M Patel

Vinodkumar Gupta

Sunil S Nadkarni

Original Assignee

Torrent Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-30

Filing date

2005-08-01

Publication date

2008-11-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35653988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1737847(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-08-01 Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd

2008-11-28 Publication of PL1737847T3 publication Critical patent/PL1737847T3/pl

Links

KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 title abstract 4
229960000619 nebivolol Drugs 0.000 title abstract 4
238000000034 method Methods 0.000 title abstract 3
150000003839 salts Chemical class 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title abstract 2
JWEXHQAEWHKGCW-VCVZPGOSSA-N (S,R,R,R)-nebivolol hydrochloride Chemical compound [Cl-].C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)C[NH2+]C[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 JWEXHQAEWHKGCW-VCVZPGOSSA-N 0.000 abstract 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
239000011230 binding agent Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
239000007884 disintegrant Substances 0.000 abstract 1
229940068174 nebivolol hydrochloride Drugs 0.000 abstract 1
239000006186 oral dosage form Substances 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
239000000080 wetting agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrane Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL05815690T 2004-07-30 2005-08-01 Nebiwolol i jego farmaceutycznie dopuszczalne sole, proces ich przygotowania i kompozycje farmaceutyczne nebiwololu PL1737847T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IN811MU2004		2004-07-30
EP05815690A EP1737847B1 (en)	2004-07-30	2005-08-01	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
PCT/IN2005/000252 WO2006025070A2 (en)	2004-07-30	2005-08-01	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol

Publications (1)

Publication Number	Publication Date
PL1737847T3 true PL1737847T3 (pl)	2008-11-28

Family

ID=35653988

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05815690T PL1737847T3 (pl)	2004-07-30	2005-08-01	Nebiwolol i jego farmaceutycznie dopuszczalne sole, proces ich przygotowania i kompozycje farmaceutyczne nebiwololu

Country Status (16)

Country	Link
US (2)	US8604222B2 (pl)
EP (2)	EP1737847B1 (pl)
JP (3)	JP5757005B2 (pl)
KR (1)	KR100896266B1 (pl)
CN (2)	CN101862322A (pl)
AT (2)	ATE397605T1 (pl)
AU (1)	AU2005278782B2 (pl)
BR (1)	BRPI0513672A (pl)
DE (1)	DE602005007339D1 (pl)
ES (1)	ES2307219T3 (pl)
HR (1)	HRP20080297T3 (pl)
MX (1)	MX2007000911A (pl)
PL (1)	PL1737847T3 (pl)
RU (1)	RU2378272C2 (pl)
WO (1)	WO2006025070A2 (pl)
ZA (1)	ZA200700765B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101862322A (zh) *	2004-07-30	2010-10-20	托伦特药物有限公司	奈必洛尔及其药学可接受盐、制备方法以及奈必洛尔的药物组合物
EP1839658A1 (en) *	2006-03-30	2007-10-03	Hexal A/S	Pharmaceutical composition comprising micronized nebivolol
EP1886674B1 (de) *	2006-08-04	2010-03-31	Alfred, E. Tiefenbacher Gmbh & Co. Kg	Pharmazeutische Zusammensetzung enthaltend Nebivolol
ITMI20061889A1 (it)	2006-10-03	2008-04-04	Zambon Spa	Processo di preparazione di nebivololo
JP5259612B2 (ja) *	2006-11-27	2013-08-07	ザックシステムエス．ピー．エー．	ネビボロールの調製法
WO2008089549A1 (en)	2007-01-22	2008-07-31	Genpharm Ulc	Pharmaceutical compositions comprising nebivolol or a nebivolol analogue
EP2162438A4 (en) *	2007-05-30	2011-07-06	Ind Swift Lab Ltd	PROCESS FOR THE PREPARATION OF IVABRADINE HYDROCHLORIDE AND CORRESPONDING POLYMORPHIDE
EP2163551B1 (en) *	2008-09-08	2011-11-16	Cadila Pharmaceuticals Ltd.	An improved process for the preparation of nebivolol hydrochloride
IT1392067B1 (it) *	2008-10-31	2012-02-09	Zach System Spa	Processo di preparazione di nebivololo
WO2010089764A2 (en) *	2009-01-05	2010-08-12	Msn Laboratories Limited	Improved process for the preparation of nebivolol hydrochloride
IT1395354B1 (it)	2009-07-23	2012-09-14	Zach System Spa	Processo di preparazione di nebivololo
DE102010005953A1 (de)	2010-01-27	2011-07-28	Corden PharmaChem GmbH, 68305	Verfahren zur Herstellung von Nebivolol
US8785664B2 (en)	2010-02-11	2014-07-22	Menarini International Operations Luxembourg S.A.	Process for the preparation of nebivolol
IT1397962B1 (it) *	2010-02-11	2013-02-04	Menarini Int Operations Lu Sa	Processo per la preparazione del nebivololo.
KR20110130872A (ko) *	2010-05-28	2011-12-06	현대약품 주식회사	결정형 염산 네비볼롤을 포함하는 약학 조성물 및 제조방법
US9456997B2 (en)	2010-08-26	2016-10-04	The Regents Of The University Of Colorado, A Body Corporate	Selective inhibition of β1-adrenergic receptors for the treatment of pediatric heart failure
IT1402974B1 (it) *	2010-11-30	2013-09-27	Menarini Int Operations Lu Sa	Processo per la preparazione del nebivololo.
US20140057954A1 (en) *	2012-08-22	2014-02-27	Forest Laboratories Holdings Ltd.	Chemical composition
ES2700973T3 (es)	2014-02-14	2019-02-20	Corden Pharma Int Gmbh	Proceso sin base para la preparación de compuestos intermedios de cetona que se pueden usar para fabricar nebivolol
EP2907810A1 (en)	2014-02-14	2015-08-19	Corden Pharma International GmbH	A new method for producing nebivolol hydrochloride of high purity
DE102014107132A1 (de)	2014-05-20	2015-11-26	Corden Pharma International Gmbh	Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind
JP6154417B2 (ja) *	2015-03-20	2017-06-28	株式会社三共	遊技機
WO2016185492A1 (en) *	2015-05-19	2016-11-24	Ipca Laboratories Limited	Process for preparation of nebivolol and it's salts
WO2017119629A1 (ko) *	2016-01-08	2017-07-13	에리슨제약(주)	용출률이 개선된 네비보롤을 포함하는 약학적 조성물
KR102203229B1 (ko) *	2016-01-08	2021-01-14	에리슨제약(주)	용출률이 개선된 네비보롤을 포함하는 약학적 조성물
ES3040411T3 (en)	2018-03-22	2025-10-30	Incarda Therapeutics Inc	A novel method to slow ventricular rate
US12576026B2 (en)	2020-07-08	2026-03-17	Extrovis Ag	Formulations of nebivolol

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7908031A (nl)	1979-11-01	1981-06-01	Acf Chemiefarma Nv	Nieuwe chinolinederivaten en farmaceutische preparaten die een dergelijke verbinding bevatten, alsmede werk- wijze voor het bereiden van deze verbindingen.
DE3033919A1 (de)	1980-09-09	1982-04-22	Bayer Ag, 5090 Leverkusen	Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
DE3133156A1 (de) *	1981-08-21	1983-03-10	Herberts Gmbh, 5600 Wuppertal	Verfahren zum markieren von verkehrsflaechen und vorrichtung hierfuer
US4654362A (en)	1983-12-05	1987-03-31	Janssen Pharmaceutica, N.V.	Derivatives of 2,2'-iminobisethanol
CA1337429C (en) *	1983-12-05	1995-10-24	Guy Rosalia Eugene Van Lommen	Derivatives of 2,2'-iminobisethanol
DE3419131A1 (de)	1984-05-23	1985-11-28	Bayer Ag, 5090 Leverkusen	Dihydropyridinkombinationspraeparate und verfahren zu ihrer herstellung
US4681765A (en)	1984-09-13	1987-07-21	American Home Products Corporation	Rapid releasing triamterene containing gelatin capsule dosage forms for once daily antihypertensive use
US4904477A (en)	1987-07-08	1990-02-27	American Home Products Corporation	Spray dried ibuprofen compositions
US6545040B1 (en)	1988-03-23	2003-04-08	Janssen Pharmaceutica N.V.	Method of lowering the blood pressure
CA1337432C (en) *	1988-03-23	1995-10-24	Raymond M. Xhonneux	Method of lowering the blood pressure
US4911921A (en)	1989-02-02	1990-03-27	Mallinckrodt, Inc.	High ibuprofen content granulations
ZA93436B (en)	1992-01-24	1993-08-25	Chugai Pharmaceutical Co Ltd	Benzopyran derivatives
TW355683B (en) *	1994-02-17	1999-04-11	Janssen Pharmaceutica Nv	Composition containing micronized nebivolol
DE69528585D1 (de)	1994-05-16	2002-11-21	Cell Therapeutics Inc	Asymmetrische synthese von chiralen sekondären alkoholen
JP3993651B2 (ja)	1994-10-21	2007-10-17	アスビオファーマ株式会社	シクロプロパクロメンカルボン酸誘導体
SK282144B6 (sk)	1994-12-28	2001-11-06	Janssen Pharmaceutica N. V.	Liečivo na terapeutické a profylaktické ošetrenie degeneratívnych chorôb vaskulárneho systému a nervovej sústavy, ktoré súvisia s oxidačným stresom
WO1997029160A1 (en)	1996-02-09	1997-08-14	Surface Solutions Laboratories, Inc.	Water-based hydrophilic coating compositions and articles prepared therefrom
DE69722202T2 (de) *	1996-06-07	2004-04-01	Vanderbilt University, Nashville	Dihydrobenzopyran und ähnliche verbindungen verwendbar als antientzündungsmittel
US5948440A (en)	1997-12-17	1999-09-07	Ranbaxy Laboratories Limited	Modified release matrix formulation of cefaclor and cephalexin
US6200990B1 (en) *	1998-12-21	2001-03-13	Alcon Laboratories, Inc.	Neuroprotective agents having antioxidant and NMDA antagonist activity
US6482799B1 (en)	1999-05-25	2002-11-19	The Regents Of The University Of California	Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
CA2395132A1 (en)	2000-01-05	2001-07-12	Imarx Therapeutics, Inc.	Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
BR0116994A (pt)	2001-04-27	2004-03-02	Lupin Ltd	Um processo aperfeiçoado para a preparação de uma composição que abrange uma combinação de dose fixa (fdc) de quatro drogas antituberculose
CA2446064A1 (en)	2001-05-02	2002-11-07	Nitromed, Inc.	Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
IL152573A (en)	2002-10-31	2009-11-18	Transpharma Medical Ltd	A system for the transmission through the skin of a medical preparation against vomiting and nausea
HU227236B1 (en)	2002-11-06	2010-12-28	Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag	New process for the production of racemic and the pure [2s[2r[r[r]]]]-and [2r[2s[s[s]]]]-enantiomers of nebivolol
WO2005065639A2 (en)	2003-11-21	2005-07-21	Torrent Pharmaceuticals Limited	Novel pharmaceutical compositions
CN101862322A (zh) *	2004-07-30	2010-10-20	托伦特药物有限公司	奈必洛尔及其药学可接受盐、制备方法以及奈必洛尔的药物组合物
ES2341250T3 (es)	2004-08-11	2010-06-17	Hetero Drugs Limited	Procedimiento novedoso de preparacion de intermediarios de nebivolol.
WO2006084684A1 (de)	2005-02-11	2006-08-17	Stada Arzneimittel Ag	Pharmazeutische zusammensetzungen nebivolo und ein hydrophiles polymer

2005
- 2005-08-01 CN CN201010002590A patent/CN101862322A/zh active Pending
- 2005-08-01 CN CN2005800258506A patent/CN101006081B/zh not_active Expired - Fee Related
- 2005-08-01 AT AT05815690T patent/ATE397605T1/de not_active IP Right Cessation
- 2005-08-01 BR BRPI0513672-5A patent/BRPI0513672A/pt not_active IP Right Cessation
- 2005-08-01 AT AT06021645T patent/ATE512961T1/de not_active IP Right Cessation
- 2005-08-01 PL PL05815690T patent/PL1737847T3/pl unknown
- 2005-08-01 ES ES05815690T patent/ES2307219T3/es not_active Expired - Lifetime
- 2005-08-01 MX MX2007000911A patent/MX2007000911A/es active IP Right Grant
- 2005-08-01 RU RU2007106103/04A patent/RU2378272C2/ru not_active IP Right Cessation
- 2005-08-01 HR HR20080297T patent/HRP20080297T3/xx unknown
- 2005-08-01 KR KR1020077004512A patent/KR100896266B1/ko not_active Expired - Fee Related
- 2005-08-01 JP JP2007523241A patent/JP5757005B2/ja not_active Expired - Fee Related
- 2005-08-01 AU AU2005278782A patent/AU2005278782B2/en not_active Expired - Fee Related
- 2005-08-01 WO PCT/IN2005/000252 patent/WO2006025070A2/en not_active Ceased
- 2005-08-01 US US11/658,979 patent/US8604222B2/en not_active Expired - Fee Related
- 2005-08-01 EP EP05815690A patent/EP1737847B1/en not_active Revoked
- 2005-08-01 DE DE602005007339T patent/DE602005007339D1/de not_active Expired - Lifetime
- 2005-08-01 EP EP06021645A patent/EP1741712B1/en not_active Expired - Lifetime
2007
- 2007-01-26 ZA ZA200700765A patent/ZA200700765B/xx unknown
2013
- 2013-04-09 JP JP2013081448A patent/JP2013151550A/ja active Pending
- 2013-04-09 US US13/859,226 patent/US8633241B2/en not_active Expired - Fee Related
2014
- 2014-10-27 JP JP2014218548A patent/JP5837975B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP5837975B2 (ja)	2015-12-24
ATE397605T1 (de)	2008-06-15
AU2005278782B2 (en)	2011-04-21
US8633241B2 (en)	2014-01-21
ATE512961T1 (de)	2011-07-15
RU2007106103A (ru)	2008-09-10
HRP20080297T3 (en)	2008-07-31
EP1737847B1 (en)	2008-06-04
CN101006081B (zh)	2011-02-09
ZA200700765B (en)	2008-11-26
ES2307219T3 (es)	2008-11-16
JP2013151550A (ja)	2013-08-08
EP1737847A2 (en)	2007-01-03
BRPI0513672A (pt)	2008-05-13
US8604222B2 (en)	2013-12-10
US20130296583A1 (en)	2013-11-07
AU2005278782A1 (en)	2006-03-09
RU2378272C2 (ru)	2010-01-10
US20070259950A1 (en)	2007-11-08
EP1741712B1 (en)	2011-06-15
EP1741712A2 (en)	2007-01-10
KR20070062507A (ko)	2007-06-15
JP2008508258A (ja)	2008-03-21
WO2006025070A3 (en)	2006-10-12
KR100896266B1 (ko)	2009-05-08
CN101006081A (zh)	2007-07-25
MX2007000911A (es)	2007-04-12
JP5757005B2 (ja)	2015-07-29
JP2015057407A (ja)	2015-03-26
CN101862322A (zh)	2010-10-20
EP1741712A3 (en)	2007-04-04
WO2006025070A2 (en)	2006-03-09
DE602005007339D1 (de)	2008-07-17

Publication	Publication Date	Title
ZA200700765B (en)	2008-11-26	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
MY143391A (en)	2011-05-13	Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
EE200300403A (et)	2003-12-15	N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
WO2006011050A3 (en)	2006-10-05	Pyridine derivatives
TW200621737A (en)	2006-07-01	2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
MY186650A (en)	2021-08-03	Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
MXPA05007609A (es)	2005-09-30	Antagonista de un receptor sensible al calcio.
WO2006082523A3 (en)	2006-09-28	Pharmaceutical sustained release composition of metformin
MXPA04002338A (es)	2004-06-29	Derivados de carbazol y su uso como antagonistas receptores del npy5.
UA96759C2 (en)	2011-12-12	2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MXPA05011176A (es)	2005-12-14	Derivados de carboxamida como agentes antidiabeticos.
GB0109122D0 (en)	2001-05-30	Novel compounds
TW200630364A (en)	2006-09-01	2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2007044796A3 (en)	2007-12-13	Pyridazinone compounds as calcilytics
TW200639156A (en)	2006-11-16	New compounds
GEP20104964B (en)	2010-04-26	3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
WO2004111008A3 (en)	2005-03-17	Use of a compound of formula i for making a pharmaceutical composition
WO2008004100A3 (en)	2011-06-16	Therapeutic compounds
TW200730176A (en)	2007-08-16	Formulations of quinolinones
MXPA05005340A (es)	2005-11-17	Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen.
IL181666A0 (en)	2007-07-04	Indolin-2-one pyridine derivatives, preparation and therapeutic use thereof
MX2009001572A (es)	2009-02-19	Derivados de arilpiperazina y usos de los mismos.
SE0102809D0 (sv)	2001-08-22	Novel compounds
DE60113248D1 (de)	2005-10-13	Vitronektin rezeptor antagonisten
SE0403117D0 (sv)	2004-12-21	New compounds 1